TerminatedNCT01328093

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

Medication studyAges 18–65Multiple countries

The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations: Cerritos, United States · Escondido, United States and 49 more locationsSee all locations and recruitment
Activities: Medication described in the protocol
Compensation: Payment and expense reimbursement have not been verified.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateApril 2011

Recruitment status: Terminated
Enrollment listed in the registry: 678
Sponsor: Denovo Biopharma LLC
Sponsor type: Biotech company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States, France, Belgium, ...
Age range: From 18 Years to 65 Years
Official registry ID: NCT01328093
Official title: Show the full official title
A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients With DSM-IV-TR Schizophrenia Followed by Open-Label Treatment With LY2140023

Need help understanding this study?

Leave your email and we’ll get in touch to discuss your questions and possible next steps.

Recruitment & locations

Terminated

Cerritos, United States · Escondido, United States · Garden Grove, United States

48 more locations

Long Beach, United States
Oakland, United States
Sherman Oaks, United States
Coral Gables, United States
Maitland, United States
North Miami, United States
Sanford, United States
Chicago, United States
Indianapolis, United States
Creve Coeur, United States
Princeton, United States
Willingboro, United States
Brooklyn, United States
Cedarhurst, United States
Fresh Meadows, United States
Rochester, United States
Staten Island, United States
Charlotte, United States
Beachwood, United States
Canton, United States
Oklahoma City, United States
Eugene, United States
Allentown, United States
Philadelphia, United States
Austin, United States
DeSoto, United States
Wharton, United States
Richmond, United States
Bellevue, United States
Vienna, Austria
Liège, Belgium
Ottignies, Belgium
Douai, France
Limoges, France
Nîmes, France
Toulon, France
Dresden, Germany
Oranienburg, Germany
Bialystok, Poland
Gdynia, Poland
San Juan, Puerto Rico
Bucharest, Romania
Târgu Mureş, Romania
Madrid, Spain
Seville, Spain
Vic, Spain
Luleå, Sweden
Malmö, Sweden

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Denovo Biopharma LLC.

Does this study involve medication?

Yes. The study involves medication, including LY2140023 and Aripiprazole.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me